Making Successful 212Pb-Targeted Alpha Therapy a Reality

Time: 11:00 am
day: Day Two ESC AM


  • Seeking to develop a new generation of targeted therapies against cancer, based on the unique properties of 212Pb
  • Exploring the multi-asset portfolio, including two compounds in clinical development and a diverse pipeline
  • Sharing more about AlphaMedixTM receiving Breakthrough Therapy Designation by the FDA